title: Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
authors.forename: Murat
authors.initials: M
authors.lastname: Aladag
authors.forename: Cemal
authors.initials: C
authors.lastname: Camci
authors.forename: Ye
authors.initials: Y
authors.lastname: Huang
authors.forename: Harlan
authors.initials: H
authors.lastname: Wright
authors.forename: Sayed
authors.initials: S
authors.lastname: Rizvi
authors.forename: Ahmet
authors.initials: A
authors.lastname: Gurakar
authors.forename: Kenneth
authors.initials: K
authors.lastname: Stokes
authors.forename: Anthony
authors.initials: A
authors.lastname: Sebastian
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood / Q000209:etiology; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D000509:alpha-Fetoproteins / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a